Memo Therapeutics

company

About

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
Fr23M
Industries
Biotechnology,Collaboration
Founded date
Jan 1, 2012
Number Of Employee
11 - 50
Operating Status
Active

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.

Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
Fr42M
Memo Therapeutics has raised a total of Fr42M in funding over 2 rounds. Their latest funding was raised on Feb 16, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 16, 2022 Series B Fr23M 2 Detail
Nov 6, 2020 Series B Fr14M 2 Detail
May 9, 2018 Series A Fr5M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
Memo Therapeutics is funded by 3 investors. Verve Ventures and GF Group Holding are the most recent investors.
Investor Name Lead Investor Funding Round
Verve Ventures Series B
GF Group Holding Series B
Jaquet Partners Series B